



BIODIEM LTD

ABN 20 096 845 993

Level 4,

100 Albert Rd,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: [www.biodiem.com](http://www.biodiem.com)

## Announcement

### BioDiem Prospectus Update

**Melbourne, 4 March 2014:** Australian infectious disease therapy and vaccine development company BioDiem Ltd is pleased to announce the exercise of 6,151,157 options at an exercise price of 8c which has contributed \$492,093 to the company.

This exercise of options has impacted on the information in the prospectus dated and lodged with ASIC on 21 February 2014. Therefore the company will lodge and issue a replacement prospectus with revised information to accommodate the company's new position.

The timetable for the entitlement offer will also therefore be revised and will include a new Closing Date. The new Closing Date will be advised when the replacement prospectus is lodged.

The company notes that the prospectus of 21 February 2014 has not been distributed. Accordingly no offers have been made under the prospectus, nor have acceptances or application monies been received.

**ENDS**

#### About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies while pursuing development of its own vaccines. Income comes from licence fees and royalties on sales.

The lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. BDM-L, a liver disease-targeting technology platform is underway at the University of Canberra. BioDiem's antimicrobial, BDM-I, is in preclinical development for the treatment of serious infections. BioDiem's retinal product candidate, BDM-E, being developed for retinitis pigmentosa is available for outlicence. For additional information, please visit [www.biodiem.com](http://www.biodiem.com)

#### Further information

Julie Phillips, Chief Executive Officer

BioDiem Ltd

Phone +61 3 9692 7240

Email [jphillips@biodiem.com](mailto:jphillips@biodiem.com)